Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2012 by Aichi Gakuin University.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Keiko Naruse, Aichi Gakuin University
ClinicalTrials.gov Identifier:
NCT01548274
First received: March 5, 2012
Last updated: NA
Last verified: March 2012
History: No changes posted

March 5, 2012
March 5, 2012
October 2010
October 2012   (Final data collection date for primary outcome measure)
The number and function of endothelial progenitor cells [ Time Frame: 3 months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.
Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Atherosclerosis
Drug: Sarpogrelate
Sarpogrelate 300mg/day
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
20
October 2012
October 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with atherosclerosis

Exclusion Criteria:

  • Patients with high risk of bleeding
  • Patients with pregnancy
  • Patients with allergic reaction of Salpogrelate
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01548274
AGU-65
Yes
Not Provided
Not Provided
Not Provided
Keiko Naruse, Aichi Gakuin University
Aichi Gakuin University
Not Provided
Not Provided
Aichi Gakuin University
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP